These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628). von Bubnoff N; Ihorst G; Grishina O; Röthling N; Bertz H; Duyster J; Finke J; Zeiser R BMC Cancer; 2018 Nov; 18(1):1132. PubMed ID: 30453910 [TBL] [Abstract][Full Text] [Related]
3. Ruxolitinib treatment for steroid refractory acute and chronic graft vs host disease in children: Clinical and immunological results. González Vicent M; Molina B; González de Pablo J; Castillo A; Díaz MÁ Am J Hematol; 2019 Mar; 94(3):319-326. PubMed ID: 30536806 [TBL] [Abstract][Full Text] [Related]
4. Ruxolitinib in children with steroid-refractory acute graft-versus-host disease: A retrospective multicenter study of the pediatric group of SFGM-TC. Laisne L; Neven B; Dalle JH; Galambrun C; Esvan M; Renard C; Rialland F; Sirvent A; Gandemer V; Pediatr Blood Cancer; 2020 Sep; 67(9):e28233. PubMed ID: 32614145 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of Ruxolitinib for Steroid-Refractory Chronic Graft-vs-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation. Wu H; Shi J; Luo Y; Tan Y; Zhang M; Lai X; Yu J; Liu L; Fu H; Huang H; Zhao Y JAMA Netw Open; 2021 Jan; 4(1):e2034750. PubMed ID: 33502484 [TBL] [Abstract][Full Text] [Related]
7. Efficiency and Toxicity of Ruxolitinib as a Salvage Treatment for Steroid-Refractory Chronic Graft-Versus-Host Disease. Wang D; Liu Y; Lai X; Chen J; Cheng Q; Ma X; Lin Z; Wu D; Xu Y Front Immunol; 2021; 12():673636. PubMed ID: 34276662 [TBL] [Abstract][Full Text] [Related]
8. Ruxolitinib for steroid-refractory graft versus host disease in pediatric HSCT: high response rate and manageable toxicity. Mozo Y; Bueno D; Sisinni L; Fernández-Arroyo A; Rosich B; Martínez AP; Benítez-Carabante MI; Alonso L; Uría ML; Heredia CD; Mestre-Duran C; Pascual CFB; Torres J; Losantos I; Escudero A; Ruz-Caracuel B Pediatr Hematol Oncol; 2021 May; 38(4):331-345. PubMed ID: 33661711 [TBL] [Abstract][Full Text] [Related]
9. Ruxolitinib for the Treatment of Steroid-Refractory Chronic Graft-vs-Host Disease-Another Hopeful Step Forward. Alvarnas JC JAMA Netw Open; 2021 Jan; 4(1):e2035719. PubMed ID: 33502479 [No Abstract] [Full Text] [Related]